Advertisement

Advertisement
Kidney Cancer

Addition of Nivolumab to Tivozanib Following Immune Checkpoint Inhibitor Treatment in Metastatic Renal Cell Carcinoma

As reported in The Lancet by Choueiri et al, the phase III TiNivo-2 trial reported results of the immune checkpoint inhibitor rechallenge with nivolumab plus tivozanib vs tivozanib alone in patients with metastatic renal cell carcinoma following immune checkpoint inhibitor treatment.


Head and Neck Cancer

Standard Chemoradiation May Be Superior to Deintensification Approaches in Patients With HPV-Associated Oropharyngeal Cancer

Deintensified treatment involving a lower radiation dose and immunotherapy in place of chemotherapy may not perform as well as a more rigorous chemoradiation treatment approach in patients with early-stage human papillomavirus (HPV)-associated oropharyngeal cancer, according to new findings presented by Yom et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA03) and simultaneously published in the International Journal of Radiation Oncology • Biology • Physics.

 

Breast Cancer

ACS Report: Despite Overall Decreases in Breast Cancer Mortality, Incidence Rising in Key Groups

The American Cancer Society (ACS) released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States. The new report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately 517,900 breast cancer deaths. However, not all women have benefited from this progress, notably American Indian and Alaska Native (AIAN) women, whose rates have remained unchanged over the past 3 decades. Also concerning is the continued upward trend in breast cancer incidence, rising by 1% annually during 2012–2021, with the steepest increase in women younger than 50 years (1.4% per year) and Asian American/Pacific Islander (AAPI) women of any age (2.5%–2.7% per year). These findings were reported by Giaquinto et al in CA: A Cancer Journal for Clinicians


Advertisement
Prostate Cancer

Intensity-Modulated Radiation Therapy and Proton-Beam Therapy May Offer Equally High Quality of Life and Tumor Control in Patients With Localized Prostate Cancer

Two types of contemporary radiation therapy—proton-beam therapy or intensity-modulated radiation therapy—may provide comparable rates of tumor control with no differences in patient-reported quality of life among patients with low- and intermediate-risk prostate cancer, according to new findings presented by Efstathiou et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA01) and simultaneously published in the International Journal of Radiation Oncology • Biology • Physics.

 

Breast Cancer

Neo-CheckRay: Adding Durvalumab to Neoadjuvant Regimen Improves Pathologic Complete Response Rate in High-Risk Breast Cancer

Adding the immune checkpoint inhibitor durvalumab, with or without the monoclonal antibody oleclumab, to neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) significantly improved pathologic complete response rates in patients with high-risk hormone receptor (HR)-positive breast cancer, according to data presented at the European Society for Medical Oncology (ESMO) Congress 2024.

Advertisement
Advertisement




Sponsored Content

More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Health-Care Policy

Creating a Culture of Diversity, Equity, and Inclusion: Why It Matters Clinically and Ethically

The National Comprehensive Cancer Network (NCCN) has always prided itself on its commitment to evidence-based, expert consensus–driven recommendations for cancer care, with a special focus on breaking down the barriers that contribute to disparities in outcomes across all patients with cancer. With ...

Advertisement

NO-CUT Trial: Nonoperative Management of Benefit for Many Patients With Rectal Cancer

Total neoadjuvant therapy (TNT) followed by rectal surgery is the standard of care in proficient mismatch repair (pMMR) locally advanced rectal cancer, but studies are finding that patients with clinical complete response may often avoid surgery and be followed “nonoperatively.” In the first...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Solid Tumors
Issues in Oncology
Hematologic Malignancies

The Formative Years of Medical Oncology in the United States: A Rough and Tumble Road, Part 2

Vincent T. DeVita, MD George P. Canellos, MD Medical oncology had a turbulent beginning, as we explained in part 1 of this commentary published in the September 25, 2024, issue of The ASCO Post. And although no other specialty we know of struggled as much, with perseverance and time, it...

Lung Cancer

Amivantamab-vmjw Plus Lazertinib Improves Long-Term Outcomes in First-Line Setting of EGFR-Mutant Advanced NSCLC

The combination of the EGFR-MET bispecific antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib continues to demonstrate superior efficacy compared with the kinase inhibitor osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...

Novel Radioconjugate or Conventional Care Prior to Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory AML

As reported in Journal of Clinical Oncology by Gyurkocza et al, the phase III SIERRA trial has shown higher rates of durable complete remissions with the anti-CD45 radioconjugate iodine-131–apamistamab vs conventional care followed by allogeneic hematopoietic cell transplantation (allo-HCT) in...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Gynecologic Cancers

KEYNOTE-A18: Overall Survival in Cervical Cancer Improved by Pembrolizumab Plus Chemoradiotherapy

  When we add pembrolizumab, the risk of death is reduced by 33%, and that is really remarkable for this tumor [cervical cancer], which is among the worst of the gynecologic malignancies. — Domenica Lorusso, MD, PhD Tweet this quote In the phase III...

Advertisement

Atezolizumab Plus Platinum Doublet and Maintenance Niraparib for Late-Relapsing Recurrent Ovarian Cancer

As reported in the Journal of Clinical Oncology by González-Martín et al, a phase III trial (ENGOT-OV41/GEICO 69-O/ANITA) has shown no progression-free survival benefit with the addition of atezolizumab to a carboplatin doublet and maintenance niraparib in patients with recurrent ovarian cancer...

ASCO Post X Feed
Social Media Hub by Everwall